Evaxion Biotech (EVAX) has released an update. Evaxion Biotech has unveiled promising preclinical results for its cytomegalovirus vaccine program, EVX-V1, utilizing its AI-Immunology platform to ...

Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. Topline results were announced from a phase 3 study evaluating Moderna’s ...

A recent study found that a latent cytomegalovirus infection can have a negative effect on mRNA vaccine responsiveness to COVID-19 infection. Health care workers (HCWs) had a lower vaccine response to ...

Moderna just received fantastic news.

An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV ...

An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV ...

Congenital cytomegalovirus occurs in one out of every 200 babies and is the most common infectious cause of hearing loss and ...

Evaxion Biotech (EVAX) announces new positive preclinical data from its ongoing cytomegalovirus, CMV, vaccine program named EVX-V1. The data will be presented today at the 9th International Conference ...

CMV is a common virus that can cause complications in pregnant people and people with a repressed immune system. Several CMV vaccines are in development. Cytomegalovirus (CMV) is one of the most ...

An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV ...

March 19, 2009 — Cytomegalovirus (CMV) glycoprotein B vaccine may help prevent maternal and congenital CMV infection, according to the results of a phase 2, randomized, double-blind, controlled trial ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Moderna said Wednesday afternoon that its ...